1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. CRISPR Technology Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing need for new vaccines and treatments for genetic diseases
5.1.1.2. Increasing private and public investments in biotechnological and pharmaceutical sectors
5.1.2. Restraints
5.1.2.1. High cost and complexities involved in the government regulations
5.1.3. Opportunities
5.1.3.1. Advancements and improvements in CRISPR technology
5.1.3.2. Potential use of CRISPR technology in the agriculture sector
5.1.4. Challenges
5.1.4.1. Technical challenges and ethical concerns associated with CRISPR technology
5.2. Market Segmentation Analysis
5.2.1. Offering: Increasing use of CRISPR kits & reagents with the surging research activities and product improvements
5.2.2. Application: Proliferating use of CRISPR technology in the agricultural sector
5.2.3. End-User: Potential application of CRISPR technology in biotechnology companies
5.3. Market Trend Analysis
5.3.1. Increasing research and development by key players and growing application of CRISPR technology in agriculture in the Americas
5.3.2. Ongoing research and strategic collaborations for higher agricultural productivity using CRISPR technologies coupled with adoption of CRISPR in point-of-care testing in the APAC region
5.3.3. Increasing approvals for the usage of CRISPR technology for disease management coupled with growing research activities in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization
5.8.1. CRISPR becoming a viable solution for bioenergy production
5.8.2. Expanding patent landscape for CRISPR technology
6. CRISPR Technology Market, by Offering
6.1. Introduction
6.2. Product
6.3.1. Enzymes
6.3.2. Guide RNA
6.3.3. Kits & Reagents
6.3. Services
6.4.1. Cell Line Engineering
6.4.2. gRNA Design & Vector Construction
6.4.3. Screening Services
7. CRISPR Technology Market, by Application
7.1. Introduction
7.2. Agricultural
7.3. Biomedical
7.4. Industrial
8. CRISPR Technology Market, by End User
8.1. Introduction
8.2. Academics & Government Research Institutes
8.3. Biotechnology Companies
8.4.1. Agricultural Companies
8.4.2. Pharmaceutical Companies
9. Americas CRISPR Technology Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific CRISPR Technology Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa CRISPR Technology Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. Sherlock Biosciences to Acquire Sense Biodetection
12.3.1.2. Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
12.3.2. Agreement, Collaboration, & Partnership
12.3.2.1. ERS Genomics Limited (‘ERS’) Completes Licensing Agreement With Syngene International
12.3.2.2. Integrated DNA Technologies and Aldevron Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers
12.3.2.3. Bedoukian Research Inc. Partners with Inscripta to Sustainably Develop and Manufacture Naturally Produced Ingredients
12.3.2.4. Scribe Announces Collaboration to Accelerate In Vivo CRISPR-Based Genetic Medicines
12.3.3. New Product Launch & Enhancement
12.3.3.1. RoslinCT Manufacture CRISPR-Based Therapy
12.3.3.2. Revvity’s (RVTY) New Launch to Widen Access to Editing Technology
12.3.3.3. Vertex Teases Launch Plans for First Crispr Gene Editing Therapy Ahead of FDA Decision
12.3.4. Investment & Funding
12.3.4.1. Pencil Biosciences Raises GBP 5.6 Million to Advance Gene Editing for Rare Diseases
12.3.5. Award, Recognition, & Expansion
12.3.5.1. First Human CRISPR Drug Moves Forward
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Agilent Technologies, Inc.
13.1.2. Applied StemCell, Inc.
13.1.3. Beam Therapeutics Inc.
13.1.4. Caribou Biosciences, Inc.
13.1.5. Cellectis S.A.
13.1.6. CRISPR Therapeutics AG
13.1.7. Danaher Corporation
13.1.8. Editas Medicine, Inc.
13.1.9. ERS Genomics Limited
13.1.10. Function Oncology
13.1.11. GeneCopoeia, Inc.
13.1.12. GenScript Biotech Corporation
13.1.13. Horizon Discovery Group Ltd. by Revvity, Inc.
13.1.14. Inscripta, Inc.
13.1.15. Intellia Therapeutics, Inc.
13.1.16. Lonza Group Ltd.
13.1.17. Mammoth Biosciences, Inc.
13.1.18. Merck KGaA
13.1.19. New England Biolabs, Inc.
13.1.20. OriGene Technologies, Inc.
13.1.21. Prime Medicine, Inc.
13.1.22. Scribe Therapeutics
13.1.23. Sherlock Biosciences, Inc.
13.1.24. Synthego Corporation
13.1.25. Takara Holdings Inc.
13.1.26. Thermo Fisher Scientific Inc.
13.1.27. ToolGen, Inc.
13.1.28. TriLink BioTechnologies by Maravai Intermediate Holdings, LLC
13.1.29. Twist Bioscience Corporation
13.1.30. Verve Therapeutics, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
